❭ Research by medical division ❭ Cancer Medicine ❭ Institute for Cancer Research ❭ Dept. of Cancer Genetics ❭ Translational studies on solid tumours [Helland] ❭ Clinical trials ❭ IMPRESS-Norway ❭

IMPRESS-Norway

– A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer

  • EudraCT number: 2023-507894-16-00
  • Clinicaltrials.gov: NCT04817956
About the study
Study design
Collaborative partners
Update/publications

 

 
Scroll to top

Home Dept. of Cancer Genetics Translational studies on solid tumours [Helland]

  • Group members
  • Clinical trials
    • DART
    • NIPU
    • COM-IT-2
    • MATRIX-RARE
    • IMPRESS-Norway
  • Translational studies
  • Publications
  • News

Recent publications

Rakaee M, Kwiatkowski DJ (2026)
Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction-Reply
JAMA Oncol (in press)
DOI 10.1001/jamaoncol.2026.1287, PubMed 42133333

Ayuda-Durán P, Hanes R, Rønneberg L, Alver TN, Øy GF, Hauge S, Andersen AN, Egeland EV, Juell S, Nakken S, Asenso TQ, Zucknick M, Syljuåsen RG, Mælandsmo GM, Hovig E, Enserink JM (2026)
Systematic interrogation of drug sensitivities in melanoma reveals potent synergistic and antagonistic drug combinations with translational potential
Commun Med (Lond) (in press)
DOI 10.1038/s43856-026-01583-w, PubMed 42062484

Chen C, Cheng J, Hou R, Zheng X, Su L, Bjaanæs MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Christiani DC, Chen F, Cao X, Zhang R (2026)
DNA methylation and expression of MAPRE3 affect overall survival of early-stage non-small cell lung cancer patients
Mol Oncol (in press)
DOI 10.1002/1878-0261.70260, PubMed 42033322

More publications

Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority.

Webmaster for research pages: Trond Olav Berg

Cookie policy

Accessibility statement (in Norwegian)